74results about How to "Reduce tumor burden" patented technology

The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used to enhance vaccination, increase synthesis of and enhance function of blood cell components and enhance anti-neoplastic effects of various agents. The compounds of the invention can be used to produce a variety of further pharmacologic effects.

Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and / or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing CD40L in a cell and increasing tumor specific immune response and apoptosis in a subject, as well as to uses of the oncolytic adenoviral vector of the invention for producing CD40L in a cell and increasing tumor specific immune response and apoptosis, while decreasing tumor-associated immunosuppression, in a subject.

Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.

Disclosed are conjugates comprising the annexin 1-binding peptide IFLLWQR covalently linked to a therapeutic or detectable agent. Also disclosed are compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. The disclosed targeting is useful for treatment of, for example, cancer.

Disclosed herein are compositions and methods for the treatment of liver metastases in a subject. The methods include hepatic arterial infusion (HAI) of chimeric antigen receptor modified T cells (CAR-T) which are highly specific for tumor antigens such as carcinoembryonic antigen (CEA). The HAI method is optimized to maximize exposure of the modified cells to the metastatic cells while minimizing exposure to healthy cells. The methods include co-administration of a second therapeutic agent, such as IL-2.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and / or inhibit transcription in the subject.

The present disclosure provides agents for treating and / or preventing resistance of tumor cells to radiation therapy (RT), the use and relevant method thereof.

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated LyP-1 peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

The invention relates to a composition containing immunoregulatory polynucleotide serving as a therapeutic agent (such as immunization therapy). Further, the invention relates to application of the composition to treatment of diseases such as cancer.

The present invention provides biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.

Presented herein are methods for the treatment of oncological disorders by the co-administration of Coenzyme Q10 and immune checkpoint modulators. The Coenzyme Q10 formulations may be at least one of intravenous, topical, or by inhalation. Co-administration of the Coenzyme Q10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells comprising antigen recognizing receptors (e.g., chimeric antigen receptors (CARs) or T cell receptors (TCRs)), and expressing increased level of IL-18. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and resistant to immunosuppression and / or have enhanced immune-activating properties.

The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.

A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.

The invention provides a tumor imaging and treatment probe of a targeted follicle-stimulating hormone receptor as well as a preparation method and application of the tumor imaging and treatment probe,aiming at accurately identifying a focus in an operation and increasing specific imaging on the basis of the advantage of a near-infrared fluorescent dye for imaging. The tumor imaging and treatmentprobe FSH-Rh760 of the targeted follicle-stimulating hormone receptor is formed by coupling follicle-stimulating hormone polypeptide (LYTRDLVYKDPARPKIQKTCTF) and the near-infrared fluorescent dye Rh760. The tumor imaging and treatment probe has the advantages that ovarian cancer cells are identified in a targeted manner by utilizing high expression of FSHR in ovarian cancer based on a principle ofspecific binding of the FSH polypeptide and the FSHR. The tumor imaging and treatment probe has good application prospects in fluorescent imaging and fluorescent guided operations by utilizing the advantages of deeper penetration depth and lower background signals of the near-infrared fluorescent dye Rh760. The targeted probe FSH-Rh760 can be used for photothermal therapy of the ovarian cancer, and is used as a supplement of operative treatment to improve prognosis of the ovarian cancer.

The invention relates to the field of biological medicine, in particular to fusion protein containing a chimeric antigen receptor and application of the fusion protein. The fusion protein is prepared from the chimeric antigen receptor, 2A peptide, a first signal peptide, a Sirp alpha structural domain and IgG1 Fc which are sequentially connected in series; and the chimeric antigen receptor comprises an scFv region, a hinge region, a transmembrane domain and an intracellular signal transduction region. The Sirf CAR T cell can relieve tumor load and improve the survival rate of tumor-bearing mice, has no obvious blood toxicity and side effects, and has good clinical application potential. The SIRP alpha-Fc fusion protein can enhance the anti-apoptosis and memory phenotype of CAR T cells and change the immune microenvironment of tumor tissues.

The invention provides a research method for identifying NK cell depletion in bone marrow of an AML patient and application of the research method. The method comprises the following steps: researching the maturity phenotype of NK cells in bone marrow when an AML patient relapses, and after determining the maturity of the NK cells, researching whether an inhibitory receptor is in overexpression on the NK cells when the AML patient relapses based on a receptor marker; and then, further researching the anti-tumor function change and multiplication capacity of the NK cells after recurrence of the AML patient and analyzing transcriptomics to identify the depletion phenomenon of the NK cells in the bone marrow of the AML patient. According to the method provided by the invention, a systematic research method is provided for NK cell depletion caused by leukemia for the first time, the NK cell depletion phenomenon of AML relapse patients after HSCT is proved, and meanwhile, high-frequency expression of NKG2A + NK cells is related to the relapse risk. Therefore, the research method provided by the invention has a huge application value in researching and judging whether the NK cells of the AML patient after HSCT are depleted or not.

Thymosin-alpha1 is used as an adjuvant in combination with carmustine (BCNU) as an effective treatment for malignant glioblastoma.

The invention belongs to the technical field of medicinal preparations, and relates to a mesenchymal stem cell-based fusion cancer cell membrane bionic nanoparticle, in particular to a mesenchymal stem cell-based tumor and bone metastatic tumor targeted fusion cancer cell membrane bionic nanoparticle (TB@NP) and a preparation method and application thereof. The bionic nanoparticle is a drug-loadednanoparticle, and is coated with a layer of fusion cell membrane; the fusion membrane consists of a mesenchymal stem cell membrane and a cancer cell membrane, and is made into a bionic nano drug delivery system capable of targeting tumors and tumor bone metastatic parts. The bionic nanoparticle can be an inorganic nanoparticle and organic nanoparticle, and entrapped drugs can be gene drugs, smallmolecule drugs and the like. In-vivo and in-vitro experiments prove that the bionic nano delivery system can accurately deliver drugs to tumors and tumor bone metastatic parts, is high in targeting property and high in safety, can enhance the curative effect of the drugs and reduce toxic and side effects, and has relatively high clinical practice significance.

The invention belongs to the technical field of medicines, and relates to a pharmaceutical composition for treating the non-small cell lung cancer, in particular to a pharmaceutical composition composed of a Hedgehog inhibitor and a cell autophagy inhibitor or a preparation method. The Hedgehog inhibitor in the pharmaceutical composition cannot effectively inhibit proliferation of non-small cell lung cancer tumors when being used alone, and after the Hedgehog inhibitor is used in combination with the autophagy inhibitor, the tumor burden of a mouse can be rapidly relieved, and the expression of a key prognostic protein molecule GLI2 of the mouse can be inhibited; meanwhile, the pharmaceutical composition also has a remarkable treatment effect on wild EGFR type tumors; the pharmaceutical composition has no obvious influence on the weight of the mouse, so that the pharmaceutical composition is proved to have no obvious drug toxicity in an experiment period; and the pharmaceutical composition has the characteristics of high targeting property, stable curative effect and the like, and is expected to become a new generation of medicine for non-small cell lung cancer treatment.

The present invention provides a pleuroperitoneal cavity effusion tumor removal and drainage device. The pleuroperitoneal cavity effusion tumor removal and drainage device comprises an internal drainage pipe, a liquid treatment component and a return pipe; a first end of the internal drainage pipe is used for extending into human body through a puncture port, a second end of the internal drainagepipe extends out of the puncture port, an inlet of the liquid treatment component communicates with a second end of the internal drainage pipe, an outlet of the liquid treatment component communicateswith a first end of the return pipe, and a second end of the return pipe extends into human body; the liquid treatment component comprises a purification unit for filtering effusion flowing out of the human body; and the return pipe is used for inputting the filtered effusion into the human body again. The pleuroperitoneal cavity effusion tumor removal and drainage device can effectively remove tumor cells in the effusion.

Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.

The invention provides methods for classifying a cancer as susceptible to transmembrane prostate androgen induced (TMEPAI)-directed therapies, and methods for treating such cancers. The field of the invention pertains generally to medicine, pathology and oncology. More particularly, it addresses the treatment of breast cancer, such as triple-negative breast cancer, using a transmembrane prostate androgen induced (TMEPAI)-directed therapy.

A new method is described for the treatment of cancer. The method utilizes two main parts. The first part is Soma, a healing herb described in the Rig Veda, the sacred scriptures of the Hindus. The second part is a composite of plant-derived substances and a mineral. When they are administered to cancer patients following the recommended therapeutic regimen, regression of the cancer results.

The use of anti-CD44 monoclonal antibody H460-16-2 for the diagnosis and treatment of cancerous tumors, and binding assays which determine the presence of cells which express a CD44 antigenic moiety which specifically binds the monoclonal antibody H460-16-2. The monoclonal antibody is optionally used in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response to tumors.

The invention provides a lung cancer marker, which is a TREM-2 protein. The marker is a membrane surface acceptor, which is specifically expressed to myeloid derived dendritic cells and mononuclear macrophage, and belongs to the immunoglobulin superfamily. The expression of TREM-2 in peripheral blood mononuclear cells of lung cancer patients and tumor-bearing mice is obviously higher than the expression of TREM-2 in peripheral blood mononuclear cells of healthy persons and normal mice. The immunohistochemical method detection shows that high expression of TREM-2 exists in the macrophage of lung cancer patients and TREM-2 is in positive correlation with the development of lung cancer. The novel tumor marker (triggering receptors expressed on myeloid cells) namely TERM-2 can be used as a molecular marker of lung cancer diagnosis and treatment, has the advantages of convenience, rapidness, little damage, and easy reexamination, can be easily accepted by the patients, has an important meaning for the clinical diagnosis and treatment of lung cancer, and has a wide application prospect.